03/02/2026
We have entered a new era of obesity medicine. The short-term results of GLP-1 agonists (like Ozempic/Wegovy) are undeniable.
But we are ignoring a massive, looming question: What happens when you stop?
The data is clear: Without an exit strategy, we are setting patients up for a "rebound" that leaves them metabolically and functionally worse off than when they started.
Here is why prescribing these drugs without behavioral support violates the core pillars of medical ethics.
📉 The Physiology of the "Rebound"
When patients take GLP-1s, up to 25–40% of the weight lost is lean mass (muscle and bone).
The danger lies in the rebound. When treatment stops (due to cost or side effects), weight comes back rapidly, but you regain mostly fat, not muscle. We are essentially prescribing sarcopenic obesity: a body that is fatter and weaker than before treatment.
A 2026 meta-analysis in the BMJ of weight loss drugs shows that after 2 years you can expect to be fatter than when you started. The behavioural weight loss pathway (drug free), while less effective to start, and some weight regained, showed you were ay least predicted to be leaner than when you started.
⚖️ The 4 Pillars of Ethical Prescribing
If we know this trajectory is likely, "prescribe and pray" is not ethically defensible.
1. Beneficence (Acting in best interest) There is benefit, but is it sustainable? If the benefit evaporates 1.4 years after stopping, have we actually helped the patient, or just rented them a temporary improvement?
2. Non-Maleficence (Do No Harm) This is the critical failure point. If a doctor prescribes a drug knowing the patient will likely stop and regain fat on a muscle-depleted body, they are facilitating predictable harm. (This is aside from the mounting litigation regarding side effects like vision loss and gastroparesis). Some experts estimate l
itigation might might cost Novo Nordisk at least $billion just on current cases.
3. Autonomy (Informed Consent) True consent isn't just listing nausea as a side effect. It requires telling the patient:
"You will likely regain the weight if you stop."
"You might end up with less muscle than you have today."
"Unless you lift weights and eat protein, you risk becoming frail." Selling the dream without the reality of the "off-ramp" violates autonomy.
4. Justice (Fairness) Who wins? The wealthy who can afford these drugs for life. Who loses? Those who can only afford a 6-month course, crash, and end up physically weaker.
🛑 The Solution: Conditional Initiation
The answer isn't to ban the drugs; it is to couple them with a strategy that survives after the prescription runs out.
Emerging data (like the McKenzie et al., 2024 Virta study) signals that metabolic correction is possible. Patients who combined deprescribing with carbohydrate-restricted nutrition and continuous support maintained clinically significant weight loss.
Ethical prescribing in 2026 requires: ✅ Muscle Preservation: Mandatory resistance training and protein targets. ✅ Honest Consent: Transparency about the rebound effect. ✅ An Exit Strategy: A proven metabolic maintenance plan.
If we don't plan for the "after," we aren't practicing medicine. We're just delaying the inevitable.
